[9] GLP-1 agonists bind to and activate GLP-1 receptors located throughout the body, including the pancreas, gastrointestinal tract, and central nervous system
Liraglutide is an injectable drug taken once a day, while semaglutide is an injectable drug taken once a week or an oral drug taken daily
Stopping treatment when needed: In certain situations, like pregnancy, pancreatitis, severe allergic reactions, or very low BMI (18.5 or below), treatment may be fully discontinued
A recent randomized clinical trial from Denmark evaluated weight loss maintenance after one of four 52-week regimens (placebo, once daily liraglutide 3.0 mg alone, supervised exercise alone, or liraglutide plus supervised exercise) in 109 adults with obesity without serious chronic illnesses, including diabetes